Transcu

Transcu: (The Edge) Drug Delivery System 2-3 yrs from commercialisation. So, that means it could be some time before shareholders see a significant improvement in earnings and cash flow. Grp CEO however believes that things are abt to turn and the co. is on the verge of commercialising a lot of the tech’s that it hold patents on. Grp is trying to come up with alternative ways of funding its expensive drug research in order to free up capital for expansion. Grp is in talks with a partner that should be able to provide the necessary capital and expertise for the commercialisation and distributipn of a skin patch that delivers the anaesthetic lidocaine. Grp has indentified a Jap life science business that has an interest in and good synergies with their business. Once the deal is sealed, grp sees potential growth coming frm Transcu’s cosmetics business, which has been burdened from some of the expenses of trying to fund the pharmaceutical space. Besides costmestics, add that there are also expansion opportunities in the green business space, and in June, Japan approved a new policy requiring utility co’s to buy electricity from renewable sources at premium prices for the nxt 20 yrs. With this ruling, expects there will be dd for Transcu’s biomass technology.